# Abaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVExtend.

> PubMed lists PMID 32665529 in Menopause (New York, N.Y.) as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2020-10 (month precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-32665529-abaloparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-06-02
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-32665529-abaloparatide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-32665529-abaloparatide-v1.json
- Content SHA-256: `6f28793b833d931d4b083a5d04e596f9765f30eebd1fa802b9087af8279fd3ce`

## Claims and source pins

### Headline

Abaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVExtend. ([`pubmed-observation-pmid-32665529-2021-06-02-e43372307349`](#source-pubmed-observation-pmid-32665529-2021-06-02-e43372307349))

### Summary

PubMed lists PMID 32665529 in Menopause (New York, N.Y.) as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2020-10 (month precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32665529-2021-06-02-e43372307349`](#source-pubmed-observation-pmid-32665529-2021-06-02-e43372307349))

### Paragraph 1

PubMed lists PMID 32665529 in Menopause (New York, N.Y.) as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2020-10 (month precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32665529-2021-06-02-e43372307349`](#source-pubmed-observation-pmid-32665529-2021-06-02-e43372307349))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-32665529-2021-06-02-e43372307349`](#source-pubmed-observation-pmid-32665529-2021-06-02-e43372307349))

## Sources

<a id="source-pubmed-observation-pmid-32665529-2021-06-02-e43372307349"></a>
- **Abaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVExtend. · retained source version 1:2021-06-02:current:e4337230734991453b318d7c5bbf1b1ebfb2976b469500c37a00c78355a67f78** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/32665529/) (`pubmed-observation-pmid-32665529-2021-06-02-e43372307349`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Abaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVExtend." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-32665529-abaloparatide-v1.json SHA-256: 6f28793b833d931d4b083a5d04e596f9765f30eebd1fa802b9087af8279fd3ce.